{"id":"cggv:ebb05334-995a-4e93-ab33-16c35929296bv1.0","type":"EvidenceStrengthAssertion","calculatedEvidenceStrength":"Limited","contributions":[{"id":"cggv:ebb05334-995a-4e93-ab33-16c35929296b_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10135","date":"2024-09-18T17:00:00.000Z","role":"Approver"},{"id":"cggv:ebb05334-995a-4e93-ab33-16c35929296b_publish_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10135","date":"2024-09-18T19:01:58.593Z","role":"Publisher"}],"curationReasons":{"id":"cg:NewCuration"},"evidence":[{"id":"cggv:ebb05334-995a-4e93-ab33-16c35929296b_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:af322e26-dc36-4de4-8692-82c819780205_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:af322e26-dc36-4de4-8692-82c819780205","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":4,"allele":{"id":"cggv:20fc85cc-d1b8-4ab7-b5db-34bd295e704c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_145059.3(FCSK):c.2980A>C (p.Lys994Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA8143836"}},"detectionMethod":"Trio sequencing did not identify any pathogenic candidates.","firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0001250","obo:HP_0000648","obo:HP_0010864","obo:HP_0001263","obo:HP_0006970","obo:HP_0001272","obo:HP_0002540","obo:HP_0000639","obo:HP_0001622","obo:HP_0002093","obo:HP_0001274","obo:HP_0002014","obo:HP_0002521","obo:HP_0034392","obo:HP_0001252","obo:HP_0011968","obo:HP_0000486"],"previousTesting":false,"sex":"Female","variant":{"id":"cggv:e4079064-c527-4e8c-af86-975789a9f888_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:20fc85cc-d1b8-4ab7-b5db-34bd295e704c"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/30503518","type":"dc:BibliographicResource","dc:abstract":"FUK encodes fucokinase, the only enzyme capable of converting L-fucose to fucose-1-phosphate, which will ultimately be used for synthesizing GDP-fucose, the donor substrate for all fucosyltransferases. Although it is essential for fucose salvage, this pathway is thought to make only a minor contribution to the total amount of GDP-fucose. A second pathway, the major de novo pathway, involves conversion of GDP-mannose to GDP-fucose. Here we describe two unrelated individuals who have pathogenic variants in FUK and who presented with severe developmental delays, encephalopathy, intractable seizures, and hypotonia. The first individual was compound heterozygous for c.667T>C (p.Ser223Pro) and c.2047C>T (p.Arg683Cys), and the second individual was homozygous for c.2980A>C (p.Lys994Gln). Skin fibroblasts from the first individual confirmed the variants as loss of function and showed significant decreases in total GDP-[","dc:creator":"Ng BG","dc:date":"2018","dc:title":"Pathogenic Variants in Fucokinase Cause a Congenital Disorder of Glycosylation."}},"rdfs:label":"CDG-9286647"},{"id":"cggv:e4079064-c527-4e8c-af86-975789a9f888","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:e4079064-c527-4e8c-af86-975789a9f888_variant_evidence_item"}],"strengthScore":0.05,"dc:description":"Reduced by half for consanguinity"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:c2e75053-fdae-4651-88f8-3f74da2bbbd7_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:c2e75053-fdae-4651-88f8-3f74da2bbbd7","type":"Proband","ageType":"AgeAtDiagnosis","ageUnit":"Months","ageValue":11,"allele":{"id":"cggv:b2c9b447-4723-44bf-aded-044a682aff17","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_145059.3(FCSK):c.1000_1018del (p.Glu335HisfsTer?)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA8143157"}},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0001263","obo:HP_0001252","obo:HP_0002540","obo:HP_0000505","obo:HP_0010864","obo:HP_0410263"],"previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"cggv:0a348ca2-8872-4b0c-a7ea-4422d815757d_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:b2c9b447-4723-44bf-aded-044a682aff17"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/34802815","type":"dc:BibliographicResource","dc:abstract":"Congenital disorders of glycosylation (CDG) is a group of rare, hereditary, multisystem disorders, predominantly affecting nervous system. There are N- and O- types of glycosylation. Fucosylation, a form of N-glycosylation, involves many enzymes. Until today, type 1 and type 2 fucosylation defects were identified, having pathogenic variants in genes encoding α-1,6-fucosyltransferase and fucokinase enzymes, respectively. In this article, a patient with type 2 fucosylation defect will be presented, with hypotonia, developmental delay and blindness and a pathogenic variant that was previously described in two patients.","dc:creator":"Özgün N","dc:date":"2022","dc:title":"A case with congenital disorder of glycosylation with defective fucosylation 2 and new mutation in FUK gene."}},"rdfs:label":"Özgün Proband"},{"id":"cggv:0a348ca2-8872-4b0c-a7ea-4422d815757d","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:0a348ca2-8872-4b0c-a7ea-4422d815757d_variant_evidence_item"}],"strengthScore":1.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:62a83f0d-332b-4dee-8756-68ac52839e15_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:62a83f0d-332b-4dee-8756-68ac52839e15","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":3,"allele":{"id":"cggv:236209cd-27db-45dc-af5d-f44ae6c79617","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_145059.3(FCSK):c.3013G>C (p.Val1005Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA8143842"}},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0012469","obo:HP_0002521"],"previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"cggv:b2f5fb59-f203-4f91-a162-294235efc4b8_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:236209cd-27db-45dc-af5d-f44ae6c79617"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/36426412","type":"dc:BibliographicResource","dc:abstract":"Congenital disorders of glycosylation (CDG) are a group of heterogeneous disorders caused by abnormal lipid or protein glycosylation. Variants in the FCSK gene have been reported to cause CDG. Defective FCSK-induced CDG (FCSK-CDG) has only been reported previously in three unrelated children.","dc:creator":"Al Tuwaijri A","dc:date":"2023","dc:title":"Congenital disorder of glycosylation with defective fucosylation 2 (FCSK gene defect): The third report in the literature with a mild phenotype."}},"rdfs:label":"Al Tuwaijri Proband"},{"id":"cggv:b2f5fb59-f203-4f91-a162-294235efc4b8","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:b2f5fb59-f203-4f91-a162-294235efc4b8_variant_evidence_item"},{"id":"cggv:b2f5fb59-f203-4f91-a162-294235efc4b8_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"qPCR showed significant reduction in FCSK expression compared to his parents and controls (Fig 1 e,f). "}],"strengthScore":0.25,"dc:description":"Reduced by half for consanguinity"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:fa8b8c18-cea8-4afa-a21a-a1e8cc1964b1_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:fa8b8c18-cea8-4afa-a21a-a1e8cc1964b1","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":3,"allele":[{"id":"cggv:9c2a016a-e634-40a3-af36-22a58c869aa0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_145059.3(FCSK):c.667T>C (p.Ser223Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA8143045"}},{"id":"cggv:86604cd3-455b-4ecc-8baf-73db1bbb82ae","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_145059.3(FCSK):c.2047C>T (p.Arg683Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA8143480"}}],"detectionMethod":"Trio sequencing did not identify any obvious pathogenic candidates. A de novo VUS in KMT2B was ruled out based on phenotype matching.","ethnicity":{"id":"cg:HispanicOrLatino"},"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"elevated CSF:plasma glycine ratio, elevated homocysteine, poor gastric emptying","phenotypes":["obo:HP_0002020","obo:HP_0002205","obo:HP_0001250","obo:HP_0002015","obo:HP_0002188","obo:HP_0030948","obo:HP_0011968","obo:HP_0010864","obo:HP_0200134","obo:HP_0002540","obo:HP_0000505","obo:HP_0002104","obo:HP_0001263","obo:HP_0001273","obo:HP_0001252","obo:HP_0034392"],"previousTesting":true,"previousTestingDescription":"Elevated CSF:plasma glycine ratio, mildly elevated blood homocysteine (18.2–22.3 μmol/L [normal range 4–14 μmol/L]) and blood methylmalonic acid (MMA) (0.94–1.2 nmol/L [normal range 0–0.5 nmol/L]), elevated B12 measurement (1,353 pg/mL [normal is 211–911 pg/mL])","sex":"Male","variant":[{"id":"cggv:0a97b269-5246-43d7-bd96-649593f394ec_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:9c2a016a-e634-40a3-af36-22a58c869aa0"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/30503518"},{"id":"cggv:eb31b79c-0da6-4144-9e0f-0b1882da93a6_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:86604cd3-455b-4ecc-8baf-73db1bbb82ae"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/30503518"}],"rdfs:label":"CDG-0440"},{"id":"cggv:eb31b79c-0da6-4144-9e0f-0b1882da93a6","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:eb31b79c-0da6-4144-9e0f-0b1882da93a6_variant_evidence_item"}],"strengthScore":0.1},{"id":"cggv:0a97b269-5246-43d7-bd96-649593f394ec","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:0a97b269-5246-43d7-bd96-649593f394ec_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:0bc10f2d-4cf9-43c5-bf3e-5c51a3e4fbf3_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:0bc10f2d-4cf9-43c5-bf3e-5c51a3e4fbf3","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":4,"allele":{"id":"cggv:1953a498-8aed-45a1-b4e1-3fee78a1de0d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_145059.3(FCSK):c.379C>A (p.Leu127Met)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA8142865"}},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0034392","obo:HP_0002540","obo:HP_0000505","obo:HP_0002093","obo:HP_0010864","obo:HP_0001250","obo:HP_0001510","obo:HP_0001273","obo:HP_0001252","obo:HP_0001263"],"previousTesting":true,"previousTestingDescription":"Extensive lab testing: acylcarnitine profile, amino acid profile, organic acid profile, pyruvate, pyruvate kinase, galactose, ammonia, lactate, Gal-1-P-uridyltransferase, succinylacetone, biotinidase, argininosuccinic acid, MCADD, VLCADD, LCHADD, Ctrulline for defects of urea cycle, GALT activity, and G6PD - all were unremarkable.","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"cggv:66bdfa53-5528-4a39-9f7d-d44bb3c62570_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:1953a498-8aed-45a1-b4e1-3fee78a1de0d"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/35718084","type":"dc:BibliographicResource","dc:abstract":"Pathogenic variants in FCSK cause Congenital Disorder of Glycosylation with Defective Fucosylation-2 (FCSK-CDG; MIM: 618,324). It is a rare autosomal recessive genetic disease caused by defects in the L-fucose kinase, which is necessary for the fucose salvage pathway. Herein, we report two novel variants in an Iranian patient, the fourth individual with FCSK-CDG described in the literature. Two homozygous variants in FCSK (rs376941268; NM_145059.3: c.379C > A, p. Leu127Met and rs543223292; NM_145059.3: c.394G > C, p. Asp132His) were identified in the proband. Sanger sequencing conducted on his unaffected parents revealed that they were heterozygous for the same variants. The proband, a four-and-a-half year old Iranian male born to consanguineous parents, manifested Intellectual disability, growth delay, ophthalmic abnormalities, seizures, speech disorder, and feeding difficulties.","dc:creator":"Manoochehri J","dc:date":"2022","dc:title":"A combination of two novels homozygous FCSK variants cause disorder of glycosylation with defective fucosylation: New patient and literature review."}},"rdfs:label":"Manoochehri Proband"},{"id":"cggv:66bdfa53-5528-4a39-9f7d-d44bb3c62570","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:66bdfa53-5528-4a39-9f7d-d44bb3c62570_variant_evidence_item"}],"strengthScore":0.05,"dc:description":"Reducing by half for consanguinity"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:ebb05334-995a-4e93-ab33-16c35929296b_ar_el","type":"EvidenceLine","specifiedBy":"GeneValidityOverallAutosomalRecessiveVariantEvidenceCriteria","strengthScore":3.9}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":3.9},{"id":"cggv:ebb05334-995a-4e93-ab33-16c35929296b_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:ebb05334-995a-4e93-ab33-16c35929296b_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:9a0df7cf-71cd-40eb-9e10-8217e546aed9","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:2f32d7cb-6a7d-457b-9700-0ad102f5a289","type":"Finding","demonstrates":{"id":"cg:BiochemicalFunctionB"},"dc:description":"Both patient fibroblasts (CDG-0440) and knockout cells exhibited a loss of fucokinase activity.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30503518","rdfs:label":"Ng Cell Knockout"}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":0.5},{"id":"cggv:ebb05334-995a-4e93-ab33-16c35929296b_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:c72a80a3-9478-4155-97dd-d37f1ebd0883","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"cggv:52a57c59-4336-4eb6-9d6f-55322780bfc9","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"Both patients cells (Ng, 2018) and model cells showed no significant changes in cell surface fucosylation. ","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/38722107","type":"dc:BibliographicResource","dc:abstract":"FCSK-congenital disorder of glycosylation (FCSK-CDG) is a recently discovered rare autosomal recessive genetic disorder with defective fucosylation due to mutations in the fucokinase encoding gene, FCSK. Despite the essential role of fucokinase in the fucose salvage pathway and severe multisystem manifestations of FCSK-CDG patients, it is not elucidated which cells or which types of fucosylation are affected by its deficiency.","dc:creator":"Fazelzadeh Haghighi M","dc:date":"2024","dc:title":"Novel insight into FCSK-congenital disorder of glycosylation through a CRISPR-generated cell model."},"rdfs:label":"CRISPR/Cas9 Cell KO Model"}],"specifiedBy":"GeneValidityCellCultureModelOrganismCriteria","strengthScore":0,"dc:description":"Awarding 0 points because it is unclear if fucosylation is the reason for decreased NOTCH3 mRNA expression (while this is likely, fucosylation of NOTCH3 was not measured). Both human patients and the KO cell line showed no change in cell surface fucosylation, but that does not contribute to our understanding of this disease."}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":0}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":0.5}],"evidenceStrength":"Limited","sequence":8985,"specifiedBy":"GeneValidityCriteria10","strengthScore":4.4,"subject":{"id":"cggv:07051a8e-5a60-4cb8-9b4c-13ddafd70765","type":"GeneValidityProposition","disease":"obo:MONDO_0020777","gene":"hgnc:29500","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","dc:description":"FCSK was first reported in relation to autosomal recessive congenital disorder of glycosylation with defective fucosylation 2 in 2018 (Ng et al., PMID: 30503518). Six unique variants (missense and frameshift) that have been reported in five probands in four publications are included in this curation. This gene-disease relationship is also supported by the biochemical function of FCSK, which is a fucokinase that functions in the salvage pathway to generate GDP-fucose. Both a proband and a CRISPR/Cas9-based cell line knockout model exhibited defects in fucokinase activity (Ng et al., PMID: 30503518). In summary, there is limited evidence to support this gene-disease relationship. Although more evidence is needed to support a causal role, no convincing evidence has emerged that contradicts the gene-disease relationship. This classification was approved by the ClinGen Congenital Disorders of Glycosylation GCEP on the meeting date September 18, 2024 (SOP Version 10).","dc:isVersionOf":{"id":"cggv:ebb05334-995a-4e93-ab33-16c35929296b"},"@context":{"@vocab":"http://dataexchange.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"http://dataexchange.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"http://dataexchange.clinicalgenome.org/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"}}}